We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.

AusPAR: Eribulin mesilate

Australian Public Assessment Report

AusPAR

AusPAR: Eribulin Mesilate [PDF, 891.33 KB]

AusPAR: Eribulin Mesilate [DOCX, 1.18 MB]

Attachment: Product Information: Eribulin Mesilate [PDF, 399.47 KB]

Attachment: Product Information: Eribulin Mesilate [DOCX, 391 KB]

Attachment: Extract from Clinical Evaluation Report: Eribulin Mesilate [PDF, 2.18 MB]

Attachment: Extract from Clinical Evaluation Report: Eribulin Mesilate [DOCX, 4.44 MB]

Device/Product Name

Halaven

Active ingredients

Eribulin mesilate

AusPAR Date

12 October 2017

Published

1 November 2017

Submission Number

PM-2015-04001-1-4

Submission Type

Extension of indications

Decision

Approved

Product types

Prescription medicines